

Citation:

... a (10%) a b e a e (10%), e e
... a e e e a f l. f. e. e e b a e
f e e e e e e e e e e e a e a
a a e e b e a e e a
e e f. e e. A a e e S e S b
f e a e a e a e a e f a e e e a e
e e y
A e a f b e f SA e e a e e

- in PET oncology (Review). *Int J Oncol* 22: 253-267.
5. Koehler L, Gagnon K, McQuarrie S, Wuest F (2010) Iodine-124: a promising positron emitter for organic PET chemistry. *Molecules* 15: 2686-2718.
 6. Fonslet J, Koziorowski J (2013) Dry distillation of radioiodine from TeO₂ targets. *Appl Sci* 3: 675-683.
 7. Lubberink M, Herzog H (2011) Quantitative imaging of ¹²⁴I and ⁸⁶Y with PET. *Eur J Nucl Med Mol Imaging* 38 Suppl 1: S10-18.
 8. Braghirolli AM, Weissmann W, da Silva JB, dos Santos GR (2014) Production of iodine-124 and its applications in nuclear medicine. *Appl Radiat Isot* 90: 138-148.
 9. Cascini GL, Niccoli Asabella A, Notaristefano A, Restuccia A, Ferrari C, et al. (2014) ¹²⁴Iodine: a longer-life positron emitter isotope-new opportunities in molecular imaging. *Biomed Res Int* 2014: 672094.
 10. Sgouros G, Hobbs RF, Atkins FB, Van Nostrand D, Ladenson PW, et al. (2011) Three-dimensional radiobiological dosimetry (3D-RD) with ¹²⁴I PET for ¹³¹I therapy of thyroid cancer. *Eur J Nucl Med Mol Imaging* 38 Suppl 1: S41-47.
 11. Van Nostrand D, Moreau S, Bandaru VV, Atkins F, Chennupati S, et al. (2010) ¹²⁴I positron emission tomography versus ¹³¹I planar imaging in the identification of residual thyroid tissue and/or metastasis in patients who have well-differentiated thyroid cancer. *Thyroid* 20: 879-883.
 12. Moroz MA, Serganova I, Zanzonico P, Ageyeva L, Beresten T, et al. (2007) Imaging hNET reporter gene expression with ¹²⁴I-MIBG. *J Nucl Med* 48: 827-836.
 13. Simões MV, Miyagawa M, Reder S, Städele C, Haubner R, et al. (2005) Myocardial kinetics of reporter probe ¹²⁴I-FIAU in isolated perfused rat hearts after in vivo adenoviral transfer of herpes simplex virus type 1 thymidine kinase reporter gene. *J Nucl Med* 46: 98-105.
 14. Kraeber-Bodéré F, Rousseau C, Bodet-Milin C, Mathieu C, Guérard F et al. (2015) Tumor immunotargeting using innovative radionuclides. *Int J Mol Sci* 16: 3932-3954.
 15. van Dongen GA, Visser GW, Lub-de Hooge MN, de Vries EG, Perk LR (2007) Immuno-PET: a navigator in monoclonal antibody development and applications. *Oncologist* 12: 1379-1389.
 16. Qiu-e C, Zhide H, Zubi L, Jialin W, Qiheng, X (1998) Highly sensitive spectrophotometric determination of trace amounts of tellurium(IV) with the tungstate-basic dyes-poly(vinyl alcohol) system. *Analyst* 123: 695-698.
 17. Alvarenga L, Ferreira D, Altekruze D, Menezes JC, Lochmann D (2008) Tablet identification using near-infrared spectroscopy (NIRS) for pharmaceutical quality control. *J Pharm Biomed Anal* 48: 62-69.
 18. FDA (2015) Analytical Procedures and Methods Validation for Drugs and Biologics. Guidance for Industry. Food and Drug Administration.
 19. Wilbur DS (1992) Radiohalogenation of proteins: an overview of radionuclides, labeling methods, and reagents for conjugate labeling. *Bioconjug Chem* 3: 433-470.
 20. Kloster G, Laufer P (1983) Determination of specific activity of radiohalide preparations (⁷⁵Br, ⁷⁷Br, ¹²³I, ¹³¹I) by HPLC-UV detection following chemical derivatization to 1-halonaphthol-2. *J Labelled Comp Radiopharm* 20: 1305-1315.